Granulocytopenia and cancer therapy. Past problems, current solutions, future challenges

Area of Science:

• Oncology
• Infectious Diseases
• Hematology

Background:

• Granulocytopenia, a decrease in granulocyte count, is a significant complication of cancer and its treatment.
• Low granulocyte counts (<500/mm3) increase the risk of life-threatening infections, impacting cancer treatment design and patient mortality.
• While historically a major cause of death, advancements in supportive care have improved outcomes for cancer patients with granulocytopenia.

Purpose of the Study:

• To review the impact of granulocytopenia on cancer therapy and patient outcomes.
• To highlight the importance of supportive care, including infection prevention and management, in cancer patients.
• To discuss current and future strategies for managing granulocytopenia and associated infections.

Main Methods:

• Review of existing literature on granulocytopenia in cancer patients.
• Analysis of the role of supportive care interventions, such as antibiotic and antifungal therapy.
• Discussion of challenges and advancements in managing infections in immunocompromised cancer patients.

Main Results:

• Early empiric antibiotic therapy has significantly reduced mortality from bacterial infections in febrile granulocytopenic patients.
• Emergence of fungal infections as a significant threat, with early empiric antifungal therapy showing promise in reducing mortality.
• Granulocyte transfusions have shown limited success due to technical deficiencies.

Conclusions:

• Effective management of granulocytopenia and prevention of infections are crucial for realizing the full potential of cancer therapy.
• Continued efforts in refining management strategies and developing methods to improve host defenses and prophylaxis are essential.
• Advances in antimicrobial therapy offer new options, but the emergence of fungal pathogens requires further attention.